Qualigen therapeutics announces four posters on qn-302 presented at the american association of cancer research (aacr) 2023 annual meeting in orlando, fl

Carlsbad, calif., april 18, 2023 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or “the company,” nasdaq: qlgn), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, while also commercializing diagnostics, today announces data from the company's four posters regarding its' lead program, qn-302, was presented at the american association for cancer research (aacr) annual meeting 2023 held april 14-19 in orlando, fl.
QLGN Ratings Summary
QLGN Quant Ranking